Lippincott, Williams & Wilkins, The Pediatric Infectious Disease Journal, 8(29), p. 774-777, 2010
DOI: 10.1097/inf.0b013e3181db741b
Full text: Download
Highly active antiretroviral therapy might lead to the development of dyslipidemia and lipodystrophy (LD) syndrome. We carried out a multicenter prospective study of 22 human immunodeficiency virus (HIV)-1-infected children treated during 48 months with lopinavir/ritonavir-based highly active antiretroviral therapy to evaluate the trend of serum lipids and adipokines. Increase in plasma leptin levels and leptin/adiponectin ratio was associated with LD. These adipokines may be surrogate markers of LD.